-+ 0.00%
-+ 0.00%
-+ 0.00%

Processa net loss narrows to $3.27 million in Q2 2026

PUBT·08/14/2026 20:13:20
Listen to the news
Processa net loss narrows to $3.27 million in Q2 2026
  • Processa posted a net loss of USD 3.27 million for the quarter ended June 30, 2026, narrowing from USD 3.93 million.
  • Operating loss improved to USD 2.34 million from USD 3.95 million, while revenue remained at no revenue.
  • Research and development expense fell to USD 649,877 from USD 2.45 million, due to lower NGC-Cap Phase 2 trial costs.
  • General and administrative expense rose to USD 1.69 million from USD 1.5 million, driven mainly by higher professional fees.
  • July brought the Vidya acquisition and a USD 200 million gross private placement, with USD 183.3 million net to fund operations into 2H 2029.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Processa Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038334), on August 14, 2026, and is solely responsible for the information contained therein.